University of Minnesota Technology Commercialization Office

Submit a New Inquiry

Technology #2019-131 - Monoclonal Anti-FAP for cancer research and therapeutic development

University of Minnesota Technology Commercialization Office contracts with Nouvant to provide this service.

Your inquiry will be sent to this technology's managers. All fields are required unless otherwise noted.

Optional

Optional

By submitting this inquiry you accept the terms of the Privacy Policy and Terms of Service.

Powered by Nouvant